Biopharmaceutical company developing cancer treatments, including a WEE1 inhibitor.
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Zentalis Pharmaceuticals, Inc..
The 1 sources with the most insights about Zentalis Pharmaceuticals, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The host mentioned its WEE1 inhibitor program for platinum-resistant ovarian cancer but was unsure about the company's plans and offered no view on its prospects.
The host mentioned its WEE1 inhibitor program for platinum-resistant ovarian cancer but was unsure about the company's plans and offered no view on its prospects.
Other assets that creators frequently mention in the same content as Zentalis Pharmaceuticals, Inc..
The most active sources covering Zentalis Pharmaceuticals, Inc. (ZNTL) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Zentalis Pharmaceuticals, Inc. (ZNTL) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Zentalis Pharmaceuticals, Inc. (ZNTL) most frequently also discuss ASML, 000660, CCL, TXN, AAOI. See the "Discussed alongside" section above for full asset pages.